Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma

Myoung Ha Lee, Seungup Kim, doyoung kim, SangHoon Ahn, Eun Hee Choi, Kwang Hun Lee, Do Yun Lee, Jinsil Seong, KwangHyub Han, Chae Yoon Chon, Junyong Park

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background and Aim: The clinical utility of alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) as a predictor of treatment outcome in patients with advanced hepatocellular carcinoma (HCC) receiving hepatic artery infusional chemotherapy (HAIC) or concurrent chemoradiation therapy (CCRT) has been poorly defined. Methods: Between January 2003 and December 2007, we enrolled 127 treatment-naïve patients who received HAIC (n=60) or CCRT (n=67) as an initial treatment modality. An AFP or DCP response was defined as a reduction of more than 20% from the baseline level. Results: AFP responders showed significantly better overall survival (OS) than non-responders among patients with HAIC (median 17.3 vs 6.4months, P<0.001) and with CCRT (median 17.6 vs 8.7months, P=0.014). DCP responders in the CCRT group also showed significantly better progression-free survival (PFS) than non-responders (median 9.2 vs 3.1months, P<0.001). Multivariate Cox regression analyses showed that AFP response was independently predictive of OS in both groups (P=0.009 in HAIC and P=0.008 in CCRT) whereas DCP only predicted PFS in patients with CCRT (P=0.015). Conclusions: Early on-treatment AFP response was predictive of OS in treatment-naïve patients with advanced HCC receiving HAIC and CCRT as an initial treatment modality. Furthermore, DCP response was useful for predicting PFS in patients with CCRT.

Original languageEnglish
Pages (from-to)313-322
Number of pages10
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume27
Issue number2
DOIs
Publication statusPublished - 2012 Jan 1

Fingerprint

alpha-Fetoproteins
Hepatocellular Carcinoma
Hepatic Artery
Prothrombin
Drug Therapy
Therapeutics
Disease-Free Survival
Survival
acarboxyprothrombin
Group Psychotherapy
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Gastroenterology
  • Hepatology

Cite this

@article{dfb8bb977cbc427abfa5a6834f8f0c9c,
title = "Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma",
abstract = "Background and Aim: The clinical utility of alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) as a predictor of treatment outcome in patients with advanced hepatocellular carcinoma (HCC) receiving hepatic artery infusional chemotherapy (HAIC) or concurrent chemoradiation therapy (CCRT) has been poorly defined. Methods: Between January 2003 and December 2007, we enrolled 127 treatment-na{\"i}ve patients who received HAIC (n=60) or CCRT (n=67) as an initial treatment modality. An AFP or DCP response was defined as a reduction of more than 20{\%} from the baseline level. Results: AFP responders showed significantly better overall survival (OS) than non-responders among patients with HAIC (median 17.3 vs 6.4months, P<0.001) and with CCRT (median 17.6 vs 8.7months, P=0.014). DCP responders in the CCRT group also showed significantly better progression-free survival (PFS) than non-responders (median 9.2 vs 3.1months, P<0.001). Multivariate Cox regression analyses showed that AFP response was independently predictive of OS in both groups (P=0.009 in HAIC and P=0.008 in CCRT) whereas DCP only predicted PFS in patients with CCRT (P=0.015). Conclusions: Early on-treatment AFP response was predictive of OS in treatment-na{\"i}ve patients with advanced HCC receiving HAIC and CCRT as an initial treatment modality. Furthermore, DCP response was useful for predicting PFS in patients with CCRT.",
author = "Lee, {Myoung Ha} and Seungup Kim and doyoung kim and SangHoon Ahn and Choi, {Eun Hee} and Lee, {Kwang Hun} and Lee, {Do Yun} and Jinsil Seong and KwangHyub Han and Chon, {Chae Yoon} and Junyong Park",
year = "2012",
month = "1",
day = "1",
doi = "10.1111/j.1440-1746.2011.06867.x",
language = "English",
volume = "27",
pages = "313--322",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma

AU - Lee, Myoung Ha

AU - Kim, Seungup

AU - kim, doyoung

AU - Ahn, SangHoon

AU - Choi, Eun Hee

AU - Lee, Kwang Hun

AU - Lee, Do Yun

AU - Seong, Jinsil

AU - Han, KwangHyub

AU - Chon, Chae Yoon

AU - Park, Junyong

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background and Aim: The clinical utility of alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) as a predictor of treatment outcome in patients with advanced hepatocellular carcinoma (HCC) receiving hepatic artery infusional chemotherapy (HAIC) or concurrent chemoradiation therapy (CCRT) has been poorly defined. Methods: Between January 2003 and December 2007, we enrolled 127 treatment-naïve patients who received HAIC (n=60) or CCRT (n=67) as an initial treatment modality. An AFP or DCP response was defined as a reduction of more than 20% from the baseline level. Results: AFP responders showed significantly better overall survival (OS) than non-responders among patients with HAIC (median 17.3 vs 6.4months, P<0.001) and with CCRT (median 17.6 vs 8.7months, P=0.014). DCP responders in the CCRT group also showed significantly better progression-free survival (PFS) than non-responders (median 9.2 vs 3.1months, P<0.001). Multivariate Cox regression analyses showed that AFP response was independently predictive of OS in both groups (P=0.009 in HAIC and P=0.008 in CCRT) whereas DCP only predicted PFS in patients with CCRT (P=0.015). Conclusions: Early on-treatment AFP response was predictive of OS in treatment-naïve patients with advanced HCC receiving HAIC and CCRT as an initial treatment modality. Furthermore, DCP response was useful for predicting PFS in patients with CCRT.

AB - Background and Aim: The clinical utility of alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) as a predictor of treatment outcome in patients with advanced hepatocellular carcinoma (HCC) receiving hepatic artery infusional chemotherapy (HAIC) or concurrent chemoradiation therapy (CCRT) has been poorly defined. Methods: Between January 2003 and December 2007, we enrolled 127 treatment-naïve patients who received HAIC (n=60) or CCRT (n=67) as an initial treatment modality. An AFP or DCP response was defined as a reduction of more than 20% from the baseline level. Results: AFP responders showed significantly better overall survival (OS) than non-responders among patients with HAIC (median 17.3 vs 6.4months, P<0.001) and with CCRT (median 17.6 vs 8.7months, P=0.014). DCP responders in the CCRT group also showed significantly better progression-free survival (PFS) than non-responders (median 9.2 vs 3.1months, P<0.001). Multivariate Cox regression analyses showed that AFP response was independently predictive of OS in both groups (P=0.009 in HAIC and P=0.008 in CCRT) whereas DCP only predicted PFS in patients with CCRT (P=0.015). Conclusions: Early on-treatment AFP response was predictive of OS in treatment-naïve patients with advanced HCC receiving HAIC and CCRT as an initial treatment modality. Furthermore, DCP response was useful for predicting PFS in patients with CCRT.

UR - http://www.scopus.com/inward/record.url?scp=84862924426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862924426&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2011.06867.x

DO - 10.1111/j.1440-1746.2011.06867.x

M3 - Article

C2 - 21793906

AN - SCOPUS:84862924426

VL - 27

SP - 313

EP - 322

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 2

ER -